- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements | 1 | GlobeNewswire (USA) | ||
| Mi | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Di | Polyrizon beschafft 3,5 Mio. US-Dollar über registrierte Direktplatzierung | 2 | Investing.com Deutsch | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| Di | Polyrizon sichert sich 3,5 Mio. US-Dollar über Direktplatzierung | 1 | Investing.com Deutsch | ||
| Di | Polyrizon raises $3.5M through registered direct offering | 1 | Investing.com | ||
| 26.03. | Polyrizon reports $17.5M cash position, advances FDA discussions | 1 | Investing.com | ||
| 26.03. | Polyrizon Ltd.: Polyrizon Provides 2025 and Recent Highlights | 170 | GlobeNewswire (Europe) | Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions... ► Artikel lesen | |
| 26.03. | Polyrizon reports FY results: GAAP EPS of $4.90 | 1 | Seeking Alpha | ||
| 25.03. | Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 | 5 | GlobeNewswire (USA) | ||
| 25.03. | Polyrizon Ltd. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 24.03. | Polyrizon Signs MOU To Acquire Up To 20% Stake In Colugo; Stock Plunges In Pre-market | - | RTTNews | ||
| 24.03. | Polyrizon signs MOU to acquire 20% stake in drone maker Colugo | 3 | Investing.com | ||
| 24.03. | Polyrizon signs MOU to acquire up to 20% stake in eVTOL firm Colugo | 6 | Seeking Alpha | ||
| 24.03. | Polyrizon Ltd.: Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications | 308 | GlobeNewswire (Europe) | The Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana, Israel... ► Artikel lesen | |
| 17.03. | Polyrizon beauftragt CRO für Biokompatibilitätsstudien seiner Medizintechnik | - | Investing.com Deutsch | ||
| 17.03. | Polyrizon signs CRO agreement for biocompatibility studies | 1 | Investing.com | ||
| 17.03. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.03. | Polyrizon Ltd.: Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program | 210 | GlobeNewswire (Europe) | Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions... ► Artikel lesen | |
| 10.03. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.03. | Polyrizon Ltd.: Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study | 294 | GlobeNewswire (Europe) | Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions... ► Artikel lesen |
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,030 | -1,14 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| NOVAVAX | 7,330 | +1,52 % | Activist investor revives campaign to overhaul Novavax board | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 18,650 | -1,79 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BIOXXMED | 1,150 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,928 | -1,12 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| COSCIENS BIOPHARMA | 1,750 | -23,25 % | Cosciens Biopharma Inc: Cosciens Biopharma does not say why shares are spiking | ||
| XOMA ROYALTY | 29,600 | -0,67 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,255 | -0,40 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 | King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| ORAGENICS | 0,606 | 0,00 % | Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal... ► Artikel lesen | |
| VIVUS | - | - | VIVUS B.V.: VIVUS Reinforces QSIVA's Clinical Efficacy and Safety in Obesity Management | - QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland
AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| TENAX THERAPEUTICS | 11,700 | 0,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients... ► Artikel lesen | |
| SERES THERAPEUTICS | 7,400 | -0,54 % | Seres Therapeutics, Inc.: Seres Therapeutics to Present at CARB-X Investor Day |
POLYRIZON LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,060 (-0,54 %) liegt der Kurs bei 10,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.